Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease
Open Access
- 1 August 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (8) , e2329066
Abstract
Despite international guidelines for low-density lipoprotein cholesterol (LDL-C) reduction among patients with atherosclerotic cardiovascular disease (ASCVD), attainment of LDL-C goals often remains suboptimal in clinical practice.1-3 Consequently, opportunities to reduce the risk of death and ASCVD events remain partially unfulfilled. A meta-analysis by the Cholesterol Treatment Trialists’ (CTT) Collaboration4 of randomized clinical trials with statins demonstrated a consistent association between absolute reduction in LDL-C concentration and relative reduction in risk of death and major vascular events. Data from trials with ezetimibe appear to support this relationship with reasonable fidelity.4-6 Treatment with a high-intensity statin regimen results in an approximate 50% LDL-C reduction, while addition of ezetimibe provides a further 13% to 18% reduction in LDL-C.5,7,8 Ezetimibe is recommended as the first nonstatin agent to prescribe when LDL-C goals are not attained with an optimized statin regimen alone.1,2 However, despite ezetimibe’s safety, tolerability, and low cost, its use remains less than 10% in clinical trial populations.9-11 Optimizing lipid-lowering therapy (LLT) with both statin and ezetimibe treatment therefore offers an efficient strategy to achieve substantial LDL-C reduction and consequent clinical benefit.12-16Keywords
This publication has 34 references indexed in Scilit:
- Interpretation of the evidence for the efficacy and safety of statin therapyThe Lancet, 2016
- Implications for Ezetimibe Therapy Use Based on IMPROVE-IT CriteriaThe American Journal of Medicine, 2015
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- Association Between Statin Adherence and Cholesterol Level Reduction from Baseline in a Veteran PopulationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Impact of a Prescription Copayment Increase on Lipid-Lowering Medication Adherence in VeteransCirculation, 2009
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and ElaborationAnnals of Internal Medicine, 2007
- Absolute and Attributable Risks of Cardiovascular Disease Incidence in Relation to Optimal and Borderline Risk FactorsArchives of internal medicine (1960), 2007
- Problems due to medication costs among VA and non-VA patients with chronic illnesses.2004
- Underuse of cardioprotective medications in patients prior to acute myocardial infarctionThe American Journal of Cardiology, 2003